This information was published on 2025-04-11T10:23:37 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2536531 (IR 1847360) |
| (220) |
06 Mar 2025
|
| (300) |
US, 10 Sep 2024, 98743134
|
| (511) (510) |
Class 5
Pharmaceutical preparations; pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy; pharmaceutical preparations for frataxin replacement therapy. |
| (540) | UFRAXTA |
| (550) | Word |
| (730) |
Larimar Therapeutics, Inc.
|
Find out more about publications on the About page.